The low‐dose monoethylglycinexylidide test: Assessment of liver function with fewer side effects
C Reichel, A Nacke, T Sudhop, G Wienkoop, C Luers, C Hahn, C Pohl, U Spengler, T Sauerbruch – 30 December 2003 – The hepatic metabolism of lidocaine (1 mg/kg intravenously) to its metabolite monoethylglycinexylidide (MEG‐X) is the basis of the standard MEG‐X test. To reduce the lidocaine‐induced side effects, we evaluated the MEG‐X formation after 0.5 and 1 mg/kg lidocaine intravenously in subjects with normal (n = 5) and severely impaired liver function (n = 7) (study I).